PGI26 Within-Trial Analysis to Estimate the Economically Justifiable Price of Linaclotide in the Treatment of Irritable Bowel Syndrome With Constipation in the UK von McDonell, A, Barzey, V, Kotchie, R, Mungapen, L, Prior, M, Fortea, J

Volltext

The economic impact of overactive bladder syndrome in six Western countries von Irwin, Debra E., Mungapen, Laura, Milsom, Ian, Kopp, Zoe, Reeves, Penny, Kelleher, Con

Volltext

P84 Utility Values For COPD Patients Based on the EQ-5D Questionnaire from Three Indacaterol Phase III Studies von Asukai, Y, Baldwin, M, Mungapen, L

Volltext

PCN101 COST-UTILITY ANALYSIS OF DASATINIB AS A SECOND-LINE TREATMENT IN THE CHRONIC PHASE OF CHRONIC MYELOID LEUKAEMIA IN RUSSIA von Kuznetzov, S, Mungapen, LJ, Samyshkin, Y, Jakouloff, DE, Sbarigia, U, van Baardewijk, M

Volltext